.@VeronaPharma investor and R&amp;D webinar yesterday was an excellent example of the unmet need for a novel therapy in the 1.2m COPD patients that remain symptomatic despite maximum therapy. Read full note here by @nplus1singer #shares #stocks
https://t.co/E9qZDJlGfI https://t.co/l9OWWy3vd7